Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors

Volume: 2018, Pages: 1 - 12
Published: Jul 2, 2018
Abstract
Background . Neuroendocrine tumors (NETs) are characterized by having behavior and prognosis that depend upon tumor histology, primary site, staging, and proliferative index. The symptoms associated with carcinoid syndrome and vasoactive intestinal peptide tumors are treated with octreotide acetate. The PROMID trial assesses the effect of octreotide LAR on the tumor growth in patients with well-differentiated metastatic midgut NETs. The CLARINET...
Paper Details
Title
Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors
Published Date
Jul 2, 2018
Volume
2018
Pages
1 - 12
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.